Literature DB >> 12478728

Selective RXR modulators for the treatment of type II diabetes.

Margaret M Faul1, Timothy A Grese.   

Abstract

Retinoid X receptor (RXR) modulators are being evaluated as a means for the treatment of non-insulin dependent (type II) diabetes mellitus, and substantial progress has been made in the preclinical evaluation of these compounds. To aid in this process, several structural classes of RXR modulators are now under investigation. The diverse structures and syntheses of these compounds will be discussed in this review.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12478728

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN： 1367-6733


  3 in total

1.  Relevance of nuclear receptor expression in a Tchreg cell line, HOZOT: RXRα and PPARγ negatively regulate IFN-γ production.

Authors:  Motoyuki Suzuki; Makoto Takeuchi; Kazue Tsuji-Takayama; Akira Harashima; Takeshi Otani; Terumasa Toraya; Hiroki Kakuta; Fumiyuki Yamasaki; Shuji Nakamura; Masayoshi Kibata
Journal:  Results Immunol       Date:  2012-08-19

2.  Retinoid X receptor agonists inhibit phorbol-12-myristate-13-acetate (PMA)-induced differentiation of monocytic THP-1 cells into macrophages.

Authors:  Lei Zhou; Ling-Hong Shen; Liu-Hua Hu; Heng Ge; Jun Pu; Da-Jun Chai; Qin Shao; Li Wang; Jin-Zhang Zeng; Ben He
Journal:  Mol Cell Biochem       Date:  2009-09-27       Impact factor: 3.396

3.  Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians.

Authors:  Min-Jeong Shin; Alka M Kanaya; Ronald M Krauss
Journal:  Atherosclerosis       Date:  2007-12-03       Impact factor: 5.162
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.